PA
Parnax Lab Ltd (PARNAXLAB)
₹121.97
Mkt cap
₹147 Cr
P/E ratio
14.70
P/B
1.47
Div yield
0.00%
ROE
14.40%
ROCE
13.90%
EPS (TTM)
₹8.30
Book value
₹83
52W range
73–150
Sector
Healthcare
Price history
Previous close
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations [1]
NSE PARNAXLABBSE 506128
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−18.41% from high₹122
₹73+68.23% from low₹150
Current
₹121.97
Prev close
₹128.99
Day
−5.44%
Price performance
1D
−5.44%
1W
−1.47%
1M
−6.03%
3M
—
6M
—
1Y
—
YTD
+1.94%
Financials
Revenue, profit & margin
P/E ratio
14.7×
PARNAXLAB is 57% below the sector median of 34.6×
PARNAXLAB14.7×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48.74 | 42.61 | 50.99 | 46.37 | 50.12 | 48.36 | 40.22 | 49.04 | 53.38 | 62.60 | 62.94 | 69.63 | 56.80 | |
| Expenses | 42.24 | 37.32 | 45.02 | 40.58 | 41.50 | 41.12 | 35.95 | 42.41 | 45.94 | 54.52 | 56.09 | 64.75 | 52.49 | |
| Operating Profit | 6.50 | 5.29 | 5.97 | 5.79 | 8.62 | 7.24 | 4.27 | 6.63 | 7.44 | 8.08 | 6.85 | 4.88 | 4.31 | |
| OPM % | 13.34% | 12.41% | 11.71% | 12.49% | 17.20% | 14.97% | 10.62% | 13.52% | 13.94% | 12.91% | 10.88% | 7.01% | 7.59% | |
| Other Income | 0.24 | 0.22 | 0.10 | 0.25 | 0.11 | 0.95 | 0.19 | 0.43 | 0.18 | 0.63 | -0.17 | 1.76 | 0.15 | |
| Interest | 1.16 | 1.43 | 1.35 | 1.41 | 1.50 | 1.38 | 1.23 | 1.28 | 1.22 | 1.40 | 1.47 | 1.61 | 1.64 | |
| Depreciation | 1.60 | 1.74 | 1.78 | 1.84 | 1.83 | 1.94 | 1.79 | 1.83 | 1.94 | 2.10 | 1.96 | 2.04 | 2.22 | |
| Profit before tax | 3.98 | 2.34 | 2.94 | 2.79 | 5.40 | 4.87 | 1.44 | 3.95 | 4.46 | 5.21 | 3.25 | 2.99 | 0.60 | |
| Tax % | 16.33% | 20.09% | 25.85% | 19.35% | 26.30% | 29.77% | 16.67% | 26.08% | 26.46% | 30.33% | 16.62% | 27.09% | 28.33% | |
| Net Profit | 3.33 | 1.87 | 2.18 | 2.24 | 3.99 | 3.42 | 1.21 | 2.93 | 3.28 | 3.62 | 2.71 | 2.19 | 0.43 | |
| EPS in Rs | 2.89 | 1.63 | 1.90 | 1.95 | 3.47 | 2.97 | 1.05 | 2.54 | 2.85 | 3.16 | 2.36 | 1.90 | 0.37 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202672.30%Promoter
Promoters72.30%
Public27.71%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Parnax Lab | ₹128.20 | 14.68 | 147 | 0.00% | 0 | −86.85% | 57 | +6.41% | 13.89% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Sep - The Newspaper Advertisement regarding AGM Notice for the year ended March 31, 2026.Notice Of 44Th AGM Of The Company 7 SepReg. 34 (1) Annual Report. 7 Sep - Parnax Lab issued 44th Annual Report; AGM on 29 September 2026 with auditor and related-party approvals.Notice Of Book Closure 26 AugBoard Meeting Outcome for Outcome Of BM Held Today I.E. 26Th August, 2026 26 Aug - Board approved revised Directors’ Report and noted Secretarial Auditors’ Report for FY2026.